Valence8 US’s Vaxcyte PCVX Stock Holding History

Valence8 US’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,468	Closed	-$282K	–	49
2024 Q3	$282K	Buy	+2,468	New	+$222K	0.12%	36

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Valence8 US's PCVX Position: Q4 2024 in Review

Valence8 US sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 2,468 shares — an estimated $282K sold.

Valence8 US first reported a position in PCVX in Q3 2024 and held it in 1 quarter. The position peaked at $282K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

Valence8 US reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 2,468 Vaxcyte shares in Q4 2024, an estimated $282K.
Valence8 US first reported a position in Vaxcyte in Q3 2024 and held it in 1 quarter.
Valence8 US's Vaxcyte position peaked at $282K in Q3 2024.
323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.